The scrutiny stems from the company's first-quarter 2026 financial disclosure on April 29, 2026. During the report, GE HealthCare posted adjusted earnings per share of $0.99 and slashed its full-year guidance to a range of $4.80 to $5.00, down from the previous target of $4.95 to $5.15. Management attributed these struggles to a recall involving a pharmaceutical diagnostics (PDx) supplier and margin declines within the Patient Care Solutions (PCS) segment.

Market reaction was immediate. Shares of GEHC dropped $9.01, or 13.2%, closing at $59.49 on the day of the announcement. Shareholders seeking to participate in the inquiry or recover potential losses are encouraged to contact the Los Angeles-based firm at 310-914-5007 or via their website to discuss their legal standing.